Everything below concerns phase 2 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-07. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
6 February – Around eight million people on means tested benefits begin to receive the final scheduled cost-of-living payment from the UK government, as Sunak tells the BBC the financial pressures on households are beginning to ease. 7 February The government announces that dentists will be offered a £20,000 bonus to work in the areas of England with the poorest access to NHS care. Data published by Halifax Bank indicates that UK house prices increased by 2.5% in January 2024 when compared to the same month in 2023. The Met Office issues two amber snow warnings for the following day covering north Wales, north-west Shropshire, the Peak District and south Pennines. 8 February The UK government confirms that more than 100 school buildings containing reinforced autoclaved aerated concrete will be rebuilt or refurbished. Sir Keir Starmer insists he has no choice but to ditch Labour's £28 billion a year green investment pledge. 9 February Weather warnings remain in place as snow and rain continue to fall across the UK. Police tell reporters they believe that Abdul Shakoor Ezedi may have drowned in the River Thames, based on CCTV of the suspect at Chelsea Bridge. The Duke of Sussex settles his remaining phone hacking claims against Mirror Group Newspapers, with the newspaper agreeing to pay his legal costs along with around £300,000 in compensation. 10 February Police begin a search of the River Thames for the body of Abdul Shakoor Ezedi, the Clapham chemical attack suspect. A light aircraft crashes into the garden of a property in Bodffordd, Anglesey.
Lungs can be affected by a number of diseases and disorders. Pulmonology is the medical speciality that deals with respiratory diseases involving the lungs and respiratory system. Cardiothoracic surgery deals with surgery of the lungs including lung volume reduction surgery, lobectomy, pneumectomy and lung transplantation.
The current model of atomic structure is the quantum mechanical model. Traditional chemistry starts with the study of elementary particles, atoms, molecules, substances, metals, crystals and other aggregates of matter. Matter can be studied in solid, liquid, gas and plasma states, in isolation or in combination. The interactions, reactions and transformations that are studied in chemistry are usually the result of interactions between atoms, leading to rearrangements of the chemical bonds which hold atoms together. Such behaviors are studied in a chemistry laboratory. The chemistry laboratory stereotypically uses various forms of laboratory glassware. However glassware is not central to chemistry, and a great deal of experimental (as well as applied/industrial) chemistry is done without it.
Sources: en.wikipedia.org
but whose efficiencies are under debate. This debate is largely on the uncertainty of the number of days reduced from after infectious or detectable whichever comes first to before a symptom shows up for an infected susceptible person. If the person is infectious after symptoms show up, or detection only works for a person with symptoms, then these prevention methods are not necessary, and self-isolation and/or medical attention is the best way to cut the
=== 2004—2008: Third Michelin star and international acclaim === In 2004, the Fat Duck became the third restaurant in the UK to receive three Michelin stars, after the Waterside Inn, also in Bray, and Restaurant Gordon Ramsay in London. It was the fastest that a British restaurant had gone from one to three stars. At the time he received his third star, Blumenthal said it was the closest he had been to bankruptcy, with enough money only to cover the following week's staff wages. Immediately after receiving the third star, the Fat Duck began receiving hundreds of phone calls seeking reservations a day. Blumenthal hired Tony Baker as managing director to help deal with the demand. In the same year, the Fat Duck was ranked second in the world behind the French Laundry by the World's 50 Best Restaurants. It also received the title of Square Meal BMW Best UK Restaurant 2004. That year, food and safety officers found "borderline" levels of listeria in the foie gras and expressed concern that "no core temperatures of the meat are taken". The Daily Telegraph reported that the Fat Duck dealt with the problem and introduced "stringent procedures." In 2005, the World's 50 Best Restaurants named the Fat Duck the best restaurant in the world. At the first Front of House Awards in 2007, it won the awards for Overall Service and Front Desk of the Year. As of 2007, the Fat Duck employed 32 chefs, with a weekly wage bill of around £35,000. It seated 46 people for lunch and dinner six days a week, with an average spend of around £175 per head and an annual turnover of more than £4 million.
After the Second World War, the United States and the Soviet Union were doomed to be antagonists. ... There probably was never any real possibility that the post-1945 relationship could be anything but hostility verging on conflict. ... Traditions, belief systems, propinquity, and convenience ... all combined to stimulate antagonism, and almost no factor operated in either country to hold it back. From that view of "post-revisionism" emerged a line of inquiry that examines how Cold War actors perceived various events and the degree of misperception involved in the failure of the two sides to reach common understandings of their wartime alliance and their disputes. After the opening of the Soviet archives, John Lewis Gaddis began to argue that the Soviets should be held more accountable for conflict. According to Gaddis, Stalin was in a much better position to compromise than his Western counterparts, given his much broader power within his own regime than Truman, who was often undermined by vociferous political opposition at home. Asking if it would have been possible to predict that the wartime alliance would fall apart within a matter of months, leaving in its place nearly a half century of cold war, Gaddis wrote in his 1997 book We Now Know: Rethinking Cold War History the following:
Sources: en.wikipedia.org
About 21,000 were raised in the First World War, mainly consisting of Sikhs of Punjab and Rajputs from Rajputana (such as the Bikaner Camel Corps and the Hyderabad, Mysore and Jodhpur Lancers of the Imperial Service Cavalry Brigade). These forces played a prominent role in the Sinai and Palestine Campaign.
=== Maternal === Fetal AFP levels can be monitored in the urine of pregnant women. Since AFP is quickly cleared from the mother's serum via her kidneys, maternal urine AFP correlates with fetal serum levels, although the maternal urine level is much lower than the fetal serum level. AFP levels rise until about week 32. Maternal serum alpha-fetoprotein (MSAFP) screening is performed at 16 to 18 weeks of gestation. If MSAFP levels indicate an anomaly, amniocentesis may be offered to the patient.
== Function == While most members of the POT family catalyze peptide transport, one is a nitrate permease and one can transport histidine, as well as peptides. Some of the peptide transporters can also transport antibiotics. They function by proton symport, but the substrate:H+ stoichiometry is variable: the high-affinity rat PepT2 carrier catalyzes uptake of 2 and 3 H+ with neutral and anionic dipeptides, respectively, while the low affinity PepT1 carrier catalyzes uptake of one H+ per neutral peptide.
Later that month, he led a 31-member trade delegation on a 20-day tour to the United States, aiming to attract American investors by highlighting opportunities in Malaysia, including tax exemptions and other incentives. In June 1979, Mahathir led a 23-member delegation to Pyongyang to sign Malaysia's first trade agreement with North Korea, aimed at exploring opportunities to increase imports of North Korean products. During the visit, he also met with North Korea's supreme leader, Kim Il Sung. In August, Mahathir reported that total approved capital investment in Malaysian companies for 1978 had increased by 38.6 per cent from the previous year, rising from US$441.3 million in 1977 to US$611.4 million; the number of approved projects also increased from 400 to 428, and the number of approved projects for expansion grew from 103 in 1976 and 150 in 1977 to 190 in 1978. In December, Mahathir launched the Manpower Development Board to improve manpower training and to help make the 1980s a decade of resource-based industries. In 1981, facing health issues and advancing age, Hussein Onn decided to step down, paving the way for Mahathir to take over. In his first speech as UMNO president, Mahathir said that Malaysia and the majority Malays had a bright future, but achieving it required a just, strong, and stable government. A few days before being sworn in, Mahathir told Bernama that there would be no major changes in Malaysia's policies, particularly in foreign affairs, trade, and education, while also emphasizing Islam's continued prominence as the official religion.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.